RAD21 cohesin complex component like 1Genealiases: RAD21L · dJ545L17.2
Q-omics provides the consensus-scored RAD21L1 profile across patient tissues and cancer cell-line models. RAD21L1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAD21L1 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, RAD21L1 RNA expression shows 11,516 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where RAD21L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD21L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD21L1 survival associations across molecular data types. RAD21L1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD21L1 RNA expression–survival associations across cancer types. High RAD21L1 expression shows unfavorable associations in KIRC, CESC, LUAD and ACC, but favorable associations in SKCM and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAD21L1 RNA expression.
This table summarizes RAD21L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RAD21L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD21L1 shows lower tumor expression in PRAD and higher tumor expression in KIRP, LUAD, BRCA, CHOL and LIHC. The KIRP box plot shows higher RAD21L1 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p < 0.001).
This table shows molecular features associated with RAD21L1 in patient tissues and cancer cell lines. In patient samples, RAD21L1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD21L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and OVARY.
